Infusion of human-derived placental-derived mesenchymal stem cells in patients with acute liver failure

Phase 1

Recruiting

• Conditions: Acute liver failure.

• Registration Number: IRCT20190717044241N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

ALF: The occurrence of hepatic encephalopathy is less than 8 weeks after the onset of jaundice in a disease that does not have a history of known liver disease.
All patients with ALF or ACLF are admitted to hospital at Shariati Hospital and Imam Khomeini Hospital.

Exclusion Criteria

Patient dissatisfaction
Pregnant patient
Age less than 17 years
Patient with known active malignancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Type and amount of observed side effects due to placental mesenchymal stem cells in patients with Acute Liver Failure in order to safety assessment for this intervention. Timepoint: At 24, 48, 72 hours and one month post cell transplantation. Method of measurement: General physical assessments and laboratory tests like blood, serum, and urine analysis.;Severity of clinical scores,Consciousness Test. Timepoint: At 24, 48, 72 hours and one month post cell transplantation. Method of measurement: clinical observation by Gastroenterologist.;Assessment of Liver function. Timepoint: At 24, 48, 72 hours and one month post cell transplantation. Method of measurement: PT,INR,ALT,AST,CBC.